Risk Stratification to Predict Renal Survival in Anti-Glomerular Basement Membrane Disease.
Journal
Journal of the American Society of Nephrology : JASN
ISSN: 1533-3450
Titre abrégé: J Am Soc Nephrol
Pays: United States
ID NLM: 9013836
Informations de publication
Date de publication:
01 03 2023
01 03 2023
Historique:
received:
17
05
2022
accepted:
29
10
2022
pmc-release:
01
03
2024
pubmed:
30
11
2022
medline:
4
3
2023
entrez:
29
11
2022
Statut:
ppublish
Résumé
Most patients with anti-glomerular basement membrane (GBM) disease present with rapidly progressive glomerulonephritis, and more than half develop ESKD. Currently, no tools are available to aid in the prognostication or management of this rare disease. In one of the largest assembled cohorts of patients with anti-GBM disease (with 174 patients included in the final analysis), the authors demonstrated that the renal risk score for ANCA-associated vasculitis is transferable to anti-GBM disease and the renal histology is strongly predictive of renal survival and recovery. Stratifying patients according to the percentage of normal glomeruli in the kidney biopsy and the need for RRT at the time of diagnosis improves outcome prediction. Such stratification may assist in the management of anti-GBM disease. Prospective randomized trials investigating treatments and outcomes in anti-glomerular basement membrane (anti-GBM) disease are sparse, and validated tools to aid prognostication or management are lacking. In a retrospective, multicenter, international cohort study, we investigated clinical and histologic parameters predicting kidney outcome and sought to identify patients who benefit from rescue immunosuppressive therapy. We also explored applying the concept of the renal risk score (RRS), currently used to predict renal outcomes in ANCA-associated vasculitis, to anti-GBM disease. The final analysis included 174 patients (out of a total of 191). Using Cox and Kaplan-Meier methods, we found that the RRS was a strong predictor for ESKD. The 36-month renal survival was 100%, 62.4%, and 20.7% in the low-risk, moderate-risk, and high-risk groups, respectively. The need for renal replacement therapy (RRT) at diagnosis and the percentage of normal glomeruli in the biopsy were independent predictors of ESKD. The best predictor for renal recovery was the percentage of normal glomeruli, with a cut point of 10% normal glomeruli providing good stratification. A model with the predictors RRT and normal glomeruli ( N ) achieved superior discrimination for significant differences in renal survival. Dividing patients into four risk groups led to a 36-month renal survival of 96.4% (no RRT, N ≥10%), 74.0% (no RRT, N <10%), 42.3% (RRT, N ≥10%), and 14.1% (RRT, N <10%), respectively. These findings demonstrate that the RRS concept is transferrable to anti-GBM disease. Stratifying patients according to the need for RRT at diagnosis and renal histology improves prediction, highlighting the importance of normal glomeruli. Such stratification may assist in the management of anti-GBM disease. This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2023_02_27_JASN0000000000000060.mp3.
Sections du résumé
SIGNIFICANCE STATEMENT
Most patients with anti-glomerular basement membrane (GBM) disease present with rapidly progressive glomerulonephritis, and more than half develop ESKD. Currently, no tools are available to aid in the prognostication or management of this rare disease. In one of the largest assembled cohorts of patients with anti-GBM disease (with 174 patients included in the final analysis), the authors demonstrated that the renal risk score for ANCA-associated vasculitis is transferable to anti-GBM disease and the renal histology is strongly predictive of renal survival and recovery. Stratifying patients according to the percentage of normal glomeruli in the kidney biopsy and the need for RRT at the time of diagnosis improves outcome prediction. Such stratification may assist in the management of anti-GBM disease.
BACKGROUND
Prospective randomized trials investigating treatments and outcomes in anti-glomerular basement membrane (anti-GBM) disease are sparse, and validated tools to aid prognostication or management are lacking.
METHODS
In a retrospective, multicenter, international cohort study, we investigated clinical and histologic parameters predicting kidney outcome and sought to identify patients who benefit from rescue immunosuppressive therapy. We also explored applying the concept of the renal risk score (RRS), currently used to predict renal outcomes in ANCA-associated vasculitis, to anti-GBM disease.
RESULTS
The final analysis included 174 patients (out of a total of 191). Using Cox and Kaplan-Meier methods, we found that the RRS was a strong predictor for ESKD. The 36-month renal survival was 100%, 62.4%, and 20.7% in the low-risk, moderate-risk, and high-risk groups, respectively. The need for renal replacement therapy (RRT) at diagnosis and the percentage of normal glomeruli in the biopsy were independent predictors of ESKD. The best predictor for renal recovery was the percentage of normal glomeruli, with a cut point of 10% normal glomeruli providing good stratification. A model with the predictors RRT and normal glomeruli ( N ) achieved superior discrimination for significant differences in renal survival. Dividing patients into four risk groups led to a 36-month renal survival of 96.4% (no RRT, N ≥10%), 74.0% (no RRT, N <10%), 42.3% (RRT, N ≥10%), and 14.1% (RRT, N <10%), respectively.
CONCLUSIONS
These findings demonstrate that the RRS concept is transferrable to anti-GBM disease. Stratifying patients according to the need for RRT at diagnosis and renal histology improves prediction, highlighting the importance of normal glomeruli. Such stratification may assist in the management of anti-GBM disease.
PODCAST
This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2023_02_27_JASN0000000000000060.mp3.
Identifiants
pubmed: 36446430
pii: 00001751-202303000-00016
doi: 10.1681/ASN.2022050581
pmc: PMC10103284
doi:
Types de publication
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
505-514Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2022 by the American Society of Nephrology.
Références
Kluth DC, Rees AJ. Anti-glomerular basement membrane disease. J Am Soc Nephrol. 1999;10(11):2446-2453. doi: 10.1681/ASN.V10112446
doi: 10.1681/ASN.V10112446
McAdoo SP, Pusey CD. Anti-glomerular basement membrane disease. Clin J Am Soc Nephrol. 2017;12(7):1162-1172. doi: 10.2215/CJN.01380217
doi: 10.2215/CJN.01380217
Tang W, McDonald SP, Hawley CM, et al. Anti-glomerular basement membrane antibody disease is an uncommon cause of end-stage renal disease. Kidney Int. 2013;83(3):503-510. doi: 10.1038/ki.2012.375
doi: 10.1038/ki.2012.375
Peto P, Salama AD. Update on antiglomerular basement membrane disease. Curr Opin Rheumatol. 2011;23(1):32-37. doi: 10.1097/bor.0b013e328341009f
doi: 10.1097/bor.0b013e328341009f
Zhao J, Cui Z, Yang R, Jia XY, Zhang Y, Zhao MH. Anti-glomerular basement membrane autoantibodies against different target antigens are associated with disease severity. Kidney Int. 2009;76(10):1108-1115. doi: 10.1038/ki.2009.348
doi: 10.1038/ki.2009.348
Coche S, Sprangers B, Van Laecke S, et al. Recurrence and outcome of anti−glomerular basement membrane glomerulonephritis after kidney transplantation. Kidney Int Rep. 2021;6(7):1888-1894. doi: 10.1016/j.ekir.2021.04.011
doi: 10.1016/j.ekir.2021.04.011
van Daalen EE, Jennette JC, McAdoo SP, et al. Predicting outcome in patients with anti-GBM glomerulonephritis. Clin J Am Soc Nephrol. 2018;13(1):63-72. doi: 10.2215/CJN.04290417
doi: 10.2215/CJN.04290417
Levy JB, Hammad T, Coulthart A, Dougan T, Pusey CD. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int. 2004;66(4):1535-1540. doi: 10.1111/j.1523-1755.2004.00917.x
doi: 10.1111/j.1523-1755.2004.00917.x
McAdoo SP, Tanna A, Hrušková Z, et al. Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int. 2017;92(3):693-702. doi: 10.1016/j.kint.2017.03.014
doi: 10.1016/j.kint.2017.03.014
Alchi B, Griffiths M, Sivalingam M, Jayne D, Farrington K. Predictors of renal and patient outcomes in anti-GBM disease: clinicopathologic analysis of a two-centre cohort. Nephrol Dial Transplant. 2015;30(5):814-821. doi: 10.1093/ndt/gfu399
doi: 10.1093/ndt/gfu399
Rovin BH, Adler SG, Barratt J, et al. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4):S1-S276. doi: 10.1016/j.kint.2021.05.021
doi: 10.1016/j.kint.2021.05.021
Nasr SH, Collins AB, Alexander MP, et al. The clinicopathologic characteristics and outcome of atypical anti-glomerular basement membrane nephritis. Kidney Int. 2016;89(4):897-908. doi: 10.1016/j.kint.2016.02.001
doi: 10.1016/j.kint.2016.02.001
Marques C, Carvelli J, Biard L, et al. Prognostic factors in anti-glomerular basement membrane disease: a multicenter study of 119 patients. Front Immunol. 2019;10:1665. doi: 10.3389/fimmu.2019.01665
doi: 10.3389/fimmu.2019.01665
Jayne DR, Marshall PD, Jones SJ, Lockwood CM. Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. Kidney Int. 1990;37(3):965-970. doi: 10.1038/ki.1990.72
doi: 10.1038/ki.1990.72
Wahls TL, Bonsib SM, Schuster VL. Coexistent Wegener’s granulomatosis and anti-glomerular basement membrane disease. Hum Pathol. 1987;18(2):202-205. doi: 10.1016/S0046-8177(87)80340-4
doi: 10.1016/S0046-8177(87)80340-4
Bosch X, Mirapeix E, Font J, et al. Prognostic implication of anti-neutrophil cytoplasmic autoantibodies with myeloperoxidase specificity in anti-glomerular basement membrane disease. Clin Nephrol. 1991;36(3):107-113.
Mörtzell Henriksson M, Weiner M, Sperker W, et al. Analyses of registry data of patients with anti-GBM and antineutrophil cytoplasmatic antibody-associated (ANCA) vasculitis treated with or without therapeutic apheresis. Transfus Apher Sci. 2021;60(6):103227. doi: 10.1016/j.transci.2021.103227
doi: 10.1016/j.transci.2021.103227
Philip R, Dumont A, Martin Silva N, de Boysson H, Aouba A, Deshayes S. ANCA and anti-glomerular basement membrane double-positive patients: a systematic review of the literature. Autoimmun Rev. 2021;20(9):102885. doi: 10.1016/j.autrev.2021.102885
doi: 10.1016/j.autrev.2021.102885
Brix SR, Noriega M, Tennstedt P, et al. Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int. 2018;94(6):1177-1188. doi: 10.1016/j.kint.2018.07.020
doi: 10.1016/j.kint.2018.07.020
Brix SR, Geetha D. Keeping up with the times: prognostic tools in ANCA-associated glomerulonephritis. Clin J Am Soc Nephrol. 2020;15(8):1078-1080. doi: 10.2215/CJN.09600620
doi: 10.2215/CJN.09600620
Xia M, Yu R, Zheng Z, et al. Meta-analytical accuracy of ANCA renal risk score for prediction of renal outcome in patients with ANCA-associated glomerulonephritis. Front Med. 2021;8:736754. doi: 10.3389/fmed.2021.736754
doi: 10.3389/fmed.2021.736754
Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612. doi: 10.7326/0003-4819-150-9-200905050-00006
doi: 10.7326/0003-4819-150-9-200905050-00006
Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ 2015;350:g7594. doi: 10.1136/bmj.g7594
doi: 10.1136/bmj.g7594
Soveri I, Mölne J, Uhlin F, et al. The IgG-degrading enzyme of Streptococcus pyogenes causes rapid clearance of anti-glomerular basement membrane antibodies in patients with refractory anti-glomerular basement membrane disease. Kidney Int. 2019;96(5):1234-1238. doi: 10.1016/j.kint.2019.06.019
doi: 10.1016/j.kint.2019.06.019
Uhlin F, Szpirt W, Kronbichler A, et al. Endopeptidase cleavage of anti-glomerular basement membrane antibodies in vivo in severe kidney disease: an open-label phase 2a study. J Am Soc Nephrol. 2022;33(4):829-838. doi: 10.1681/ASN.2021111460
doi: 10.1681/ASN.2021111460